<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39314596</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Seronegative Myasthenia Gravis: A Rare Disease Triggered by SARS-CoV-2 or a Coincidence?</ArticleTitle><Pagination><StartPage>e67511</StartPage><MedlinePgn>e67511</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e67511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.67511</ELocationID><Abstract><AbstractText>Myasthenia gravis (MG) results from the production of autoantibodies against the neuromuscular junction, leading to muscle weakness. Although the exact cause is not fully understood, it is known that the onset and exacerbations of MG can occur after viral infections. We present the case of a patient with no prior history of MG with new-onset proximal muscle weakness and ptosis, following SARS-CoV-2 infection, This case underscores the potential for autoimmune diseases to be triggered by SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright © 2024, Castro Silva et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castro Silva</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital Beatriz Ângelo, Loures, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saianda Duarte</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology, Hospital Beatriz Ângelo, Loures, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues Alves</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ophthalmology, Centro Hospitalar Universitário de Lisboa Central, Lisboa, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicente</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital CUF (Companhia União Fabril) Tejo, Lisboa, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araújo</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital Beatriz Ângelo, Loures, PRT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">covid</Keyword><Keyword MajorTopicYN="N">myasthenia gravis (mg)</Keyword><Keyword MajorTopicYN="N">post-infectious myasthenia gravis</Keyword><Keyword MajorTopicYN="N">sars-cov-2 infection</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39314596</ArticleId><ArticleId IdType="pmc">PMC11417286</ArticleId><ArticleId IdType="doi">10.7759/cureus.67511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Unravelling the pathogenesis of myasthenia gravis. Vincent A. https://www.nature.com/articles/nri916. Nat Rev Immunol. 2002;2:797–804.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360217</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 and myasthenia gravis: a review of neurological implications of the SARS-COV-2. Shah SM, Yasmin F, Memon RS, et al.  https://onlinelibrary.wiley.com/doi/10.1002/brb3.2789 Brain Behav. 2022;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9759145</ArticleId><ArticleId IdType="pubmed">36306401</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Watad A, De Marco G, Mahajna H, et al. Vaccines (Basel) 2021;9:435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146571</ArticleId><ArticleId IdType="pubmed">33946748</ArticleId></ArticleIdList></Reference><Reference><Citation>High levels of neutrophil extracellular traps persist in the lower respiratory tract of critically ill patients with coronavirus disease 2019. Ouwendijk WJ, Raadsen MP, van Kampen JJ, et al.  https://academic.oup.com/jid/article/223/9/1512/6122477?login=false. J Infect Dis. 2021;223:1512–1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928833</ArticleId><ArticleId IdType="pubmed">33507309</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil extracellular trap: a key player in the pathogenesis of autoimmune diseases. Sadeghi M, Dehnavi S, Jamialahmadi T, Johnston TP, Sahebkar A. Int Immunopharmacol. 2023;116:109843.</Citation><ArticleIdList><ArticleId IdType="pubmed">36764274</ArticleId></ArticleIdList></Reference><Reference><Citation>Management of patients with generalised myasthenia gravis and COVID-19: four case reports. Hübers A, Lascano AM, Lalive PH. https://jnnp.bmj.com/content/91/10/1124. J Neurol Neurosurg Psychiatry. 2020;91:1124–1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651248</ArticleId></ArticleIdList></Reference><Reference><Citation>New-onset myasthenia gravis after SARS-CoV-2 infection: case report and literature review. Tereshko Y, Gigli GL, Pez S, De Pellegrin A, Valente M. https://link.springer.com/article/10.1007/s00415-022-11472-6. J Neurol. 2023;270:601–609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645742</ArticleId><ArticleId IdType="pubmed">36352330</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasthenia gravis associated with COVID-19 infection. Sadiq W, Waleed MS, Rizvi TA, Khan S, El Hage H. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10290576</ArticleId><ArticleId IdType="pubmed">37366447</ArticleId></ArticleIdList></Reference><Reference><Citation>New-onset ocular myasthenia gravis following SARS-CoV-2 infection. Banerjee P, Hassan H, Alam MS. Oman J Ophthalmol. 2023;16:187–188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10062107</ArticleId><ArticleId IdType="pubmed">37007275</ArticleId></ArticleIdList></Reference><Reference><Citation>Postinfectious onset of myasthenia gravis in a COVID-19 patient. Huber M, Rogozinski S, Puppe W, Framme C, Höglinger G, Hufendiek K, Wegner F. Front Neurol. 2020;11:576153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573137</ArticleId><ArticleId IdType="pubmed">33123081</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. Assini A, Gandoglia I, Damato V, Rikani K, Evoli A, Del Sette M. Eur J Neurol. 2021;28:3537–3539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014563</ArticleId><ArticleId IdType="pubmed">33421278</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasthenia gravis associated with SARS-CoV-2 infection. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Ann Intern Med. 2020;173:1027–1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429993</ArticleId><ArticleId IdType="pubmed">32776781</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasthenia gravis triggered by a COVID-19 infection: a case report and literature review. Mincă A, Mincă DI, Calinoiu AL, et al. Cureus. 2024;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11144031</ArticleId><ArticleId IdType="pubmed">38827012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocular myasthenia gravis: a review and practical guide for clinicians. Shuey NH. Clin Exp Optom. 2022;105:205–213.</Citation><ArticleIdList><ArticleId IdType="pubmed">35157811</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasthenic crisis: guidelines for prevention and treatment. Jani-Acsadi A, Lisak RP. J Neurol Sci. 2007;261:127–133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17544450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>